Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phylogica and Isogenica have entered into an agreement to use the latter's CIS display technology to optimize the performance of three of Phylogica’s compounds targeting CD40 ligand (CD40L), a key protein involved in many inflammatory diseases.
Subscribe to our email newsletter
Phylogica has already demonstrated lead peptide compounds that bind with high affinity and are biologically active against CD40L. Isogenica’s CIS display technology allows a comprehensive search process to optimize the exact chemical and three dimensional structure required to further enhance the properties of the Phylomer peptides, improving drug properties such as affinity, stability and potency.
Paul Watt, VP of corporate development at Phylogica, said: “We believe that the use of CIS display will accelerate the rapid entry of Phylogica drug candidates into preclinical development programs and increase their commercial value. Phylomers are sourced from the most structurally diverse peptide libraries in the world which translates into exceptionally high bioactive hit rates, including primary hits with picomolar affinities for their targets.”
Kevin Matthews, CEO of Isogenica, said: “Isogenica is focused on servicing the protein engineering needs of the pharmaceutical and biotech industries and is delighted to have the opportunity to work with Phylogica, combining technologies that have the potential to discover novel and potent therapeutic peptides.”